SCHEMBL25744913

SCHEMBL25744913

CC(F)Oc1ccc(F)c(C(C)(C)C)c1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ POLB P06746 2/20 0.38
▸ MAPT P10636 1/20 0.38
▸ GAA P10253 3/20 0.33
▸ ESRRA P11474 1/20 0.33
▸ ALDH1A1 P00352 1/20 0.33
▸ CA1 P00915 1/20 0.32
▸ CA2 P00918 1/20 0.32
▸ NR1H4 Q96RI1 3/20 0.32
▸ SMN1; SMN2 Q16637 1/20 0.32
▸ ATM Q13315 2/20 0.31
▸ XBP1 P17861 1/20 0.31
▸ NPSR1 Q6W5P4 1/20 0.31
▸ L3MBTL1 Q9Y468 1/20 0.31
▸ RXRA P19793 1/20 0.31
▸ GRIN1 Q05586 1/20 0.31
▸ GRIN2B Q13224 1/20 0.31
▸ CHRNA1 P02708 1/20 0.31
▸ CHRNG P07510 1/20 0.31
▸ CHRNB1 P11230 1/20 0.31
▸ CHRNB2 P17787 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24768010 0.87 POLB (0.39) POLBMAPTGAAESRRAALDH1A1
SCHEMBL7807878 0.87 POLB (0.42) POLBMAPTALDH1A1NR1H4
SCHEMBL25947021 0.79 TDP1 (0.39) POLBMAPTGAAESRRAALDH1A1
SCHEMBL10211859 0.77 CA1 (0.50) POLBMAPTGAAALDH1A1CA1
SCHEMBL26417525 0.76 KIF11 (0.39) POLBMAPTGAAESRRAALDH1A1
SCHEMBL10064799 0.74 GPR3 (0.44) POLBMAPT
SCHEMBL25635026 0.74 RORC (0.35) POLBGAASMN1; SMN2
SCHEMBL12896068 0.73 SLC6A4 (0.43) ALDH1A1RXRAHTR2ASLC6A4KCNH2
SCHEMBL19154714 0.73 POLB (0.37) POLBMAPTGAAALDH1A1RXRA
SCHEMBL13334863 0.73 NQO1 (0.46) MAPTALDH1A1SMN1; SMN2RXRAGRIN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230357254-A1 IMIDAZOPYRIDAZINES AS MODULATORS OF IL-17 JANSSEN PHARMACEUTICA NV (BE) 2023-11-09 — — US disclosed
US-11702422-B2 Imidazopyridazines as modulators of IL-17 JANSSEN PHARMACEUTICA NV (BE) 2023-07-18 — — US disclosed
US-11691979-B2 Imidazopyridazines as modulators of IL-17 JANSSEN PHARMACEUTICA NV (BE) 2023-07-04 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11691979-B2 Imidazopyridazines as modulators of IL-17 IL17A, IL23R, IL15 POLB 4678/4885MAPT 3647/4885GAA 4186/4885
US-20230357254-A1 IMIDAZOPYRIDAZINES AS MODULATORS OF IL-17 IL17A, IL23R, IL15 POLB 4678/4885MAPT 3647/4885GAA 4186/4885
US-11702422-B2 Imidazopyridazines as modulators of IL-17 IL17A, IL23R, IL15 POLB 4678/4885MAPT 3647/4885GAA 4186/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback